MedTrace Logo

Immune Boost In Non-Small Cell Lung Cancer

NCT02319408 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2022-05-23

No results posted yet for this study

Summary

Insufficient migration and activation of tumour specific effector T cells seems to be the one important reason for inadequate host anti-tumour immune response. Ionizing radiation can induce a variety of immune responses. The goal of this randomized trial is to assess if a preoperative single fraction low dose radiation is able to improve anti-tumour immune response in operable early stage lung cancer.

Conditions

Interventions

RADIATION

Preoperative radiation

Lobectomy for lung cancer following preoperative radiation

Sponsors & Collaborators

  • German Cancer Research Center

    collaborator OTHER

  • Heidelberg University

    collaborator OTHER

  • University Hospital Heidelberg

    lead OTHER

Principal Investigators

  • Seyer Safi, MD, PhD · University Hospital Heidelberg

  • Hans Hoffmann, MD, PhD · University Hospital Heidelberg

  • Peter Huber, MD, PhD · German Cancer Research Centre

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2020-02-29
Completion
2020-02-29

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02319408 on ClinicalTrials.gov